Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Buy
57
GNFT Quote, Financials, Valuation and Earnings
Last price:
$3.65
Seasonality move
:
-4.79%
Day range:
$3.73 - $3.83
52-week range:
$2.55 - $6.42
Dividend yield:
0%
P/E ratio:
32.57x
P/S ratio:
2.63x
P/B ratio:
2.63x
Volume:
1.2K
Avg. volume:
3.5K
1-year change:
-10.82%
Market cap:
$189.5M
Revenue:
$72.5M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingGenfit SA has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.70, Genfit SA has an estimated upside of 129.62% from its current price of $3.79.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.70 representing 100% downside risk from its current price of $3.79.
Fair Value
-
According to the consensus of 1 analyst, Genfit SA has 129.62% upside to fair value with a price target of $8.70 per share.
GNFT vs. S&P 500
-
Over the past 5 trading days, Genfit SA has overperformed the S&P 500 by 3.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Genfit SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genfit SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Genfit SA reported revenues of --.
Earnings Growth
-
Genfit SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Genfit SA reported earnings per share of --.
Enterprise value:
163.8M
EV / Invested capital:
--
Price / LTM sales:
2.63x
EV / EBIT:
22.19x
EV / Revenue:
2.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
10.63x
Price / Operating cash flow:
12.29x
Enterprise value / EBITDA:
17.75x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $91.6M | $21M | $30M | $6.2M | $15.4M | |
| Gross Profit | $91.4M | -- | -- | -- | -- | |
| Operating Income | $35.3M | -- | -- | -- | -- | |
| EBITDA | $88.9M | -- | -- | -- | -- | |
| Diluted EPS | $1.42 | -- | -- | -- | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $227.2M | $303.5M | $169.9M | $125M | $96.5M | |
| Total Assets | $243.7M | $319M | $231.1M | $192.2M | $157.6M | |
| Current Liabilities | $38.2M | $71.1M | $42.2M | $42.5M | $78.2M | |
| Total Liabilities | $263.9M | $184.1M | $129.8M | $117.1M | $85.5M | |
| Total Equity | -$20.2M | $134.8M | $101.4M | $75.1M | $72M | |
| Total Debt | -- | $76M | $73.7M | $71.1M | $59.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2006-03-31 | 2007-03-31 | 2008-03-31 | 2007-03-31 | 2008-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $988.3M | $1.2B | |
| Cash From Investing | -- | -- | -- | $171.6M | $239.8M | |
| Cash From Financing | -- | -- | -- | $1.8B | $2.3B | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
GNFT
Sector
Market Cap
$189.5M
$34.5M
Price % of 52-Week High
59.01%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-10.82%
-35.15%
Beta (5-Year)
1.082
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.76
200-day SMA
Sell
Level
$4.18
Bollinger Bands (100)
Sell
Level
3.46 - 4.2
Chaikin Money Flow
Buy
Level
4K
20-day SMA
Sell
Level
$3.83
Relative Strength Index (RSI14)
Sell
Level
46.78
ADX Line
Sell
Level
18.76
Williams %R
Neutral
Level
-36.3636
50-day SMA
Sell
Level
$4.10
MACD (12, 26)
Buy
Level
0.92
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-7.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.5589)
Sell
CA Score
(Annual)
Level (-0.4829)
Buy
Beneish M-Score
(Annual)
Level (-2.4545)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-9.0486)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Stock Forecast FAQ
In the current month, GNFT has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GNFT average analyst price target in the past 3 months is $8.70.
-
Where Will Genfit SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genfit SA share price will rise to $8.70 per share over the next 12 months.
-
What Do Analysts Say About Genfit SA?
Analysts are divided on their view about Genfit SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genfit SA is a Sell and believe this share price will drop from its current level to $8.70.
-
What Is Genfit SA's Price Target?
The price target for Genfit SA over the next 1-year time period is forecast to be $8.70 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GNFT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genfit SA is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of GNFT?
You can purchase shares of Genfit SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genfit SA shares.
-
What Is The Genfit SA Share Price Today?
Genfit SA was last trading at $3.65 per share. This represents the most recent stock quote for Genfit SA. Yesterday, Genfit SA closed at $3.79 per share.
-
How To Buy Genfit SA Stock Online?
In order to purchase Genfit SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
INKT alert for Jul 15
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Sell
48
NEGG alert for Jul 15
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
77
VBTX alert for Jul 15
Veritex Holdings [VBTX] is up 19.56% over the past day.
